Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy

Volume: 31, Issue: 9, Pages: 803 - 813
Published: Sep 1, 2021
Abstract
Patients having Duchenne muscular dystrophy (DMD) are currently being treated with corticosteroids, which slow down disease progression at the expense of serious adverse effects. Tamoxifen is a pro-drug some of whose metabolites interact with the nuclear estrogen receptor, leading to anti-fibrotic and muscle-protective effects as has been demonstrated in a murine model of DMD. Here we report the results from a monocentric single arm prospective...
Paper Details
Title
Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy
Published Date
Sep 1, 2021
Volume
31
Issue
9
Pages
803 - 813
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.